Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy – data from the CHOICE study

References

• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
   PubMed Web of Science ®Google Scholar
• Coiffier B. Retrospective analysis of hematological parameters and transfusion requirements in non-platinum chemotherapy-treated patients. Proc Am Soc Clin Oncol 1998;17:90a [Abstract]
   Google Scholar
• Dalton J, Bailey N, Barret-Lee P, et al. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 1998;17:418a [Abstract]
   Google Scholar
• Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92
   PubMed Web of Science ®Google Scholar
• Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-38
   PubMed Web of Science ®Google Scholar
• Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37:14-17
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-34
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar
• Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47
   PubMed Web of Science ®Google Scholar
• Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
   PubMed Web of Science ®Google Scholar
• Amgen. Aranesp: Summary of product characteristics, 2010. Available at: http://www medicines org uk/emc/medicine/4981/SPC/ARANSEP [Last accessed 2 February 2011]
   Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
   PubMed Web of Science ®Google Scholar
• Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl. 3):33-6
   PubMed Web of Science ®Google Scholar
• Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85:655-63
   PubMed Web of Science ®Google Scholar
• Charu V, Belani CP, Gill AN, et al. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist 2007;12:727-37
   PubMed Web of Science ®Google Scholar
• Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-7
   PubMed Web of Science ®Google Scholar
• Gordon D, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Oncologist 2008;13:715-24
   PubMed Web of Science ®Google Scholar
• Gregory SA. Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin's lymphoma. Support Cancer Ther 2006;3:232-9
   PubMedGoogle Scholar
• Hernandez E, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin 2009;25:2109-20
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707
   PubMed Web of Science ®Google Scholar
• Senecal FM, Yee L, Gabrail N, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005;6:446-54
   PubMedGoogle Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
   PubMed Web of Science ®Google Scholar
• Akbar A, Pasha GR, Naqvi SFH. Properties of Kaplan–Meier estimator: group comparison of survival curves. Eur J Sci Res 2009;32:391-7
   Google Scholar
• Sárosi V, Cipkova A, Móciková H, et al. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia; effects of target haemoglobin label change: data from the APRIORI study. Ann Oncol 2010;21(S8):viii-386
   Google Scholar
• Luo W, Nordstrom BL, Fraeman K, et al. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002–2006. Clin Ther 2008;30:2423-35
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Totzke U, Soling U, et al. Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia – examination of practice in Germany. Curr Med Res Opin 2008;24:2751-6
   PubMed Web of Science ®Google Scholar
• Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009;45:1603-15
   PubMed Web of Science ®Google Scholar
• Pat K, Anrys B, Verhulst D, et al. Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa. Support Care Cancer 2009;17:211-15
   PubMed Web of Science ®Google Scholar
• Van Belle S, Dalivoust P, Reinthaller A, et al. CHOICE, an international, observational study to examine current practice use of darbepoetin alfa in the management of chemotherapy-induced anaemia. Eur J Integrative Med 20091:226 [Abstract]
   Google Scholar
• Van Belle S, Dalivoust P, Reinthaller A, et al. Current practice use of darbepoetin alfa in the management of chemotherapy-induced anaemia in patients <65 years and ≥65 years: interim data from CHOICE, an international, observational study. Crit Rev Oncol Hematol 2009;72:S51-S52 [Abstract]
   Web of Science ®Google Scholar
• Van Belle S, Urbanski K, Ofreuvre H, et al. Darbepoetin alfa dosing weekly and every three weeks in cancer patients with chemotherapy-induced anaemia – efficacy data from the CHOICE study. Ann Oncol 2010;21(S8):viii-386
   Google Scholar
• Hedenus M, Adriansson M, San MJ, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
   PubMed Web of Science ®Google Scholar
• Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol 2009;27:4217-26
   PubMed Web of Science ®Google Scholar